EMA Application withdrawn: Elmisol — ACE Pharmaceuticals BV

View source ↗

Summary

The EMA withdrew the application for Elmisol from ACE Pharmaceuticals BV in the nephrotic syndrome area.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nephrotic Syndrome

Drugs mentioned

• Elmisol

Snippet

Status: Application withdrawn. Therapeutic area: Nephrotic Syndrome. MAH: ACE Pharmaceuticals BV. Decision date: 23/06/2017. Orphan medicine